November 28, 2019
Otsuka Pharmaceutical Co., Ltd.
POConePlus® Infrared Spectrophotometer for Diagnosis of H. pylori infection launched in Japan
Otsuka Pharmaceutical Co., Ltd. will market POConePlus® Infrared Spectrophotometer for diagnosis of H. pylori (Helicobacter pylori) to medical institutions across Japan from December 13, 2019.
This device is an infrared spectrophotometer that measures the change in the isotope ratio of carbon dioxide (13CO2 / 12CO2) contained in exhaled breath, to be used with a diagnostic drug component (13C- urea) to confirm the presence or absence of H. pylori.
As a successor to POCone® that Otsuka Pharmaceutical has been marketing since 2004, it features improved operability and readability by incorporating the needs of medical institutions, and colorization of the touch-panel and display. In addition, a further-enhanced device, POConePlus-AS10®, which can assess up to 10 patients, will be marketed.
Information in this news release was current as of the original release date.